FDA-cleared profile

MuscleView 2.0

Springbok, Inc. (dba Springbok Analytics) · MRI · FDA-cleared (510(k))

Authorized purpose: Automatic MRI segmentation and quantitative analysis of muscle, bone, fat, and other anatomical structures to assist visualization and measurement; not direct disease diagnosis.

Clinical role
Automated segmentation and quantitative-analysis support with clinician review and editing.
Images and patients
MRI · Muscles, bones, and adipose tissue across the lower extremities and upper body from neck to hips, plus other segmented structures
Key limitation
Keep in mind: Not intended for patients with tumors in the trunk, arms, and/or lower limbs. Segmentation results require review and editing using appropriate software. The packet establishes assistive information that may assist diagnosis when interpreted by a trained clinician, not direct standalone diagnosis.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Automatic MRI segmentation and quantitative analysis of muscle, bone, fat, and other anatomical structures to assist visualization and measurement; not direct disease diagnosis.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Muscles, bones, and adipose tissue across the lower extremities and upper body from neck to hips, plus other segmented structures Input: DICOM MRI data from adults and pediatric patients aged 18 and older; the submission describes 1.5T and 3.0T imaging and validation/model data across GE, Siemens, Philips, Canon, and Toshiba, with Toshiba limited to AI Setting 1 in the comparison.
  • Who uses it?Intended users: Trained clinicians; the packet requires segmentation results to be reviewed and edited using appropriate software.
  • What does the software produce?Output: Automatic segmentations and volumetric/dimensional metrics for individual and grouped ROIs such as muscles, bones, and adipose tissue; comparative analysis against a Virtual Control Group; Z-scores and composite scores such as a muscle-bone score.
  • What is its most important limitation?Key limitation: Not intended for patients with tumors in the trunk, arms, and/or lower limbs. Segmentation results require review and editing using appropriate software. The packet establishes assistive information that may assist diagnosis when interpreted by a trained clinician, not direct standalone diagnosis.

Clinical takeaway. Clinical role: Automatic MRI segmentation and quantitative analysis of muscle, bone, fat, and other anatomical structures to assist visualization and measurement; not direct disease diagnosis.

Evidence takeaway. Evidence from the reviewed source record: FDA testing used an independent, ground-truth-blinded test set of 148 subjects after training on 1,294 unique subjects. Expert manual segmentation was the reference standard. ROI and subgroup validation used Dice similarity coefficient or volume difference and required performance within predefined interobserver-variability acceptance ranges. The packet provides ROI/subgroup confidence intervals rather than a single device-level sensitivity, specificity, or diagnostic-accuracy estimate.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Automatic MRI segmentation and quantitative analysis of muscle, bone, fat, and other anatomical structures to assist visualization and measurement; not direct disease diagnosis.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Automated segmentation and quantitative-analysis support with clinician review and editing.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM MRI data from adults and pediatric patients aged 18 and older; the submission describes 1.5T and 3.0T imaging and validation/model data across GE, Siemens, Philips, Canon, and Toshiba, with Toshiba limited to AI Setting 1 in the comparison.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Automatic segmentations and volumetric/dimensional metrics for individual and grouped ROIs such as muscles, bones, and adipose tissue; comparative analysis against a Virtual Control Group; Z-scores and composite scores such as a muscle-bone score.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Trained clinicians; the packet requires segmentation results to be reviewed and edited using appropriate software.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Not intended for patients with tumors in the trunk, arms, and/or lower limbs. Segmentation results require review and editing using appropriate software. The packet establishes assistive information that may assist diagnosis when interpreted by a trained clinician, not direct standalone diagnosis.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA testing used an independent, ground-truth-blinded test set of 148 subjects after training on 1,294 unique subjects. Expert manual segmentation was the reference standard. ROI and subgroup validation used Dice similarity coefficient or volume difference and required performance within predefined interobserver-variability acceptance ranges. The packet provides ROI/subgroup confidence intervals rather than a single device-level sensitivity, specificity, or diagnostic-accuracy estimate.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA testing used an independent, ground-truth-blinded test set of 148 subjects after training on 1,294 unique subjects. Expert manual segmentation was the reference standard. ROI and subgroup validation used Dice similarity coefficient or volume difference and required performance within predefined interobserver-variability acceptance ranges. The packet provides ROI/subgroup confidence intervals rather than a single device-level sensitivity, specificity, or diagnostic-accuracy estimate.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

MuscleView 2.0 regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K251682
  • Samplen=148
  • IndependenceIndependence not established

K251682

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K251682. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM MRI data from adults and pediatric patients aged 18 and older; the submission describes 1.5T and 3.0T imaging and validation/model data across GE, Siemens, Philips, Canon, and Toshiba, with Toshiba limited to AI Setting 1 in the comparison.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K251682: MuscleView 2.0

  2. Routing

    Source context, not route validation: The device accepts DICOM MRI data but the FDA description says it does not directly interface with imaging devices. The reviewed packet does not establish a specific PACS, RIS, EHR, routing, or export interface.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K251682: MuscleView 2.0

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: Automatic segmentations and volumetric/dimensional metrics for individual and grouped ROIs such as muscles, bones, and adipose tissue; comparative analysis against a Virtual Control Group; Z-scores and composite scores such as a muscle-bone score.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K251682: MuscleView 2.0

  5. Viewer/worklist/report

    Unresolved route: Automatic segmentations and volumetric/dimensional metrics for individual and grouped ROIs such as muscles, bones, and adipose tissue; comparative analysis against a Virtual Control Group; Z-scores and composite scores such as a muscle-bone score.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K251682: MuscleView 2.0

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The device accepts DICOM MRI data but the FDA description says it does not directly interface with imaging devices. The reviewed packet does not establish a specific PACS, RIS, EHR, routing, or export interface.
  • Exact FDA submission
  • Checked 2026-09-08

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for MuscleView 2.0; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251682
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Muscles, bones, and adipose tissue across the lower extremities and upper body from neck to hips, plus other segmented structures
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-09-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K251682 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K251682: MuscleView 2.0

    U.S. Food and Drug Administration - Published 2025-09-09 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. MuscleView 2.0 model card (K251682)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K251682

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K251682 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K254015

CoLumbo C-Spine

Smart Soft Healthcare AD

Authorized purpose: Post-process previously acquired cervical-spine MR images to segment vertebrae and disks, calculate quantitative measurements, label out-of-range values, and export results for user review and interpretation.

Modality
MRI
Anatomy
Cervical spine: vertebrae C3-C7 and disks C2C3 through C7T1
Decision
2026-04-01
FDA-cleared K240793

MSKai

MSKai

Authorized purpose: Assist physicians in reviewing previously acquired lumbar-spine MRI by providing user-confirmed anatomy identification, segmentation, labeling, measurements, and reporting; it is not a diagnostic device.

Modality
MRI
Anatomy
Lumbar spine, including vertebral bodies L1-S1, intervertebral discs, cord canal, dural sac, nerve roots, and posterior arch.
Decision
2024-12-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history